...randomization, blinded analysis and reproduction in other labs. Kancera presents first data on CX3CR1 inhibitor Kancera AB...
...Chemokine CX3C motif receptor 1 Mary Romeo, Assistant Editor and Karen Tkach Tuzman, Associate Editor Beam Therapeutics Kancera AB Massachusetts...

...in markers for hepatic impairment were reported at the twice-daily 800 mg dose of KAND567. Kancera...
...1 (CX3CR1; Fractalkine) from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Acturum Life Sciences AB (Sodertalje, Sweden). Kancera AB...
...disease Endpoint: Safety and pharmacokinetics Status: Phase I data Milestone: NA Chris Lieu AZD8797 KAN0440567 Acturum Life Sciences AB AstraZeneca plc Kancera AB KAND567...

...IgG1 mAb specific for ROR1, in Phase I testing for refractory chronic lymphocytic leukemia (CLL). Kancera AB...

...ROR1 inhibitors, including a bispecific protein from Aptevo Therapeutics Inc. and a small molecule from Kancera AB...
...Companies and Institutions Mentioned AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Aptevo Therapeutics Inc. (NASDAQ:APVO), Seattle, Wash. Kancera AB...

...EU's Seventh Framework Programme and from partners' contributions January 2013 SEtTReND iNovacia AB subsidiary of Kancera AB...

...cell engraftment compared with IgG control. Ongoing studies include developing a humanized antibody targeting ROR1. Kancera AB...

...2010, Sprint co-founded cancer company Kancera AB and out-licensed the PFKFB3 program to the newco. "Co-founding Kancera...
...will probably seek additional funding from its investors early next year. Companies and Institutions Mentioned Kancera AB...

...Intellect partnered with Kancera's iNovacia AB subsidiary to evaluate compounds needed to optimize Intellect's Conjumab-A...
...financial details, while Kancera could not be reached. Intellect Neurosciences Inc. (OTCBB:ILNS), New York, N.Y. Kancera AB...